Therapy of Primary Refractory and Relapsed Diffuse Large B-Cell Lymphoma from the Perspective in 2022 - Theoretical Basis and Clinical Case Discussion
Journal
Journal of Internal Medicine of Taiwan
Journal Volume
32
Journal Issue
6
Pages
431-439
Date Issued
2021-12-01
Author(s)
Yu, Ta Chuan
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Approximately 30-40% of patients with this disease do not respond well to therapy, hence with poor prognosis. The opportunity of curing these patients hinges on high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation, whose intensity, however, is only tolerable to a half of this population. It is imminent to develop therapy for the patients unfit for transplant. In 2022, more and more novel therapies are being studied to treat primary refractory and relapsed DLBCL, including monoclonal antibodies (anti-CD20,-CD19,-CD79b,-CD30), Immune modulators (lenalidomide), small molecule drugs (XPO-1 inhibitor, PI3K inhibitor), immunotherapy(bispecific T-cell engager, chimeric antigen receptor T-cell therapy, immune checkpoint inhibitor). This expanding armamentarium not only brings new hopes but also challenges the physician to tailor therapy for different individuals.
Subjects
Lymphoma | Recurrence | Refractory | Therapy
SDGs
Type
journal article